Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
Trial details
- Registry ID
- NCT07516093
- Drugs studied
- NX-5948, Pirtobrutinib
TrialRedline tracks 3 clinical trials sponsored by Nurix Therapeutics, Inc.: 1 Phase 3, 1 Phase 2, 1 Phase 1 / 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLLNCT07516093 | NX-5948, Pirtobrutinib | Recruiting | 2029-10Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)NCT07221500 | NX-5948 | Recruiting | 2028-01Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study of NX-5948 in Combination With Other Agents in Adults With B-cell MalignanciesNCT07520006 | NX-5948, obinutuzumab, rituximab, venetoclax | Recruiting | 2033-05Estimated |
Names as written in the registry records.
NCT07516093 · Nurix Therapeutics, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Progression-free survival (PFS) as assessed by Independent Review Committee (IRC). After: Measure: Progression-free survival (PFS) as assessed by Independent Review Committee (IRC) Measure: Objective response rate (ORR) without partial response with lymphocytosis (PR-L) as assessed by IRC.
Before: Not yet recruiting. After: Recruiting.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Objective response rate as determined by an Independent Review Committee (IRC). After: Measure: Objective response rate without partial response with lymphocytosis (PR-L) as determined by an Independent Review Committee (IRC).